Tumor Necrosis Factor α Blockers and the Risk of Multiple Sclerosis

Affiliations

¹ From the Department of Neurology (E.M.M.S.), MS Center Amsterdam, Amsterdam University Medical Centers, The Netherlands; Department of Clinical Neurosciences (M.W.K.), University of Calgary, Canada; and Department of Community Health Sciences (M.W.K.), University of Calgary, Canada. e.strijbis@amsterdamumc.nl.
² From the Department of Neurology (E.M.M.S.), MS Center Amsterdam, Amsterdam University Medical Centers, The Netherlands; Department of Clinical Neurosciences (M.W.K.), University of Calgary, Canada; and Department of Community Health Sciences (M.W.K.), University of Calgary, Canada.

Editorial

Eva M M Strijbis et al. Neurology. 2023.

. 2023 Feb 7;100(6):267-268.

doi: 10.1212/WNL.0000000000201629. Epub 2022 Oct 28.

¹ From the Department of Neurology (E.M.M.S.), MS Center Amsterdam, Amsterdam University Medical Centers, The Netherlands; Department of Clinical Neurosciences (M.W.K.), University of Calgary, Canada; and Department of Community Health Sciences (M.W.K.), University of Calgary, Canada. e.strijbis@amsterdamumc.nl.
² From the Department of Neurology (E.M.M.S.), MS Center Amsterdam, Amsterdam University Medical Centers, The Netherlands; Department of Clinical Neurosciences (M.W.K.), University of Calgary, Canada; and Department of Community Health Sciences (M.W.K.), University of Calgary, Canada.

No abstract available

Comment on

Risk of Multiple Sclerosis Among Users of Antitumor Necrosis Factor α in 4 Canadian Provinces: A Population-Based Study.
Li L, Aviña-Zubieta JA, Bernstein CN, Kaplan GG, Tremlett H, Xie H, Peña-Sánchez JN, Marrie RA, Etminan M. Li L, et al. Neurology. 2023 Feb 7;100(6):e558-e567. doi: 10.1212/WNL.0000000000201472. Epub 2022 Oct 28. Neurology. 2023. PMID: 36307225 Free PMC article.